annb0t
Top 20
MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide therapy. (PRNewsfoto/Telix Pharmaceuticals Limited)
Illuccix remains the only PSMA-PET[3] agent approved in Australia, manufactured to GMP[4] standards, and listed on ...
>>> Read more: Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
Illuccix remains the only PSMA-PET[3] agent approved in Australia, manufactured to GMP[4] standards, and listed on ...
>>> Read more: Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
